Loading...

Paxman AB (publ)

PXMBFPNK
Healthcare
Medical - Devices
$3.50
$0.00(0.00%)

Paxman AB (publ) (PXMBF) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Paxman AB (publ) (PXMBF), covering cash flow, earnings, and balance sheets.

Revenue Growth
20.41%
20.41%
Operating Income Growth
165.54%
165.54%
Net Income Growth
382.55%
382.55%
Operating Cash Flow Growth
150.15%
150.15%
Operating Margin
12.24%
12.24%
Gross Margin
68.003%
68.003%
Net Profit Margin
8.14%
8.14%
ROE
11.67%
11.67%
ROIC
11.47%
11.47%

Paxman AB (publ) (PXMBF) Income Statement & Financial Overview

Explore comprehensive income reports for Paxman AB (publ) PXMBF, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$67.13M$66.15M$64.82M$63.41M
Cost of Revenue$22.60M$20.09M$20.66M$52.81M
Gross Profit$44.53M$46.06M$44.16M$10.60M
Gross Profit Ratio$0.66$0.70$0.68$0.17
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$18.40M$18.83M$17.25M$16.88M
Operating Expenses$38.33M$39.06M$35.67M$34.10M
Total Costs & Expenses$60.93M$59.15M$56.33M$52.81M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$11.72M$316000.00$3.44M$763000.00
Depreciation & Amortization$4.18M$4.46M$3.26M$4.17M
EBITDA$10.38M$18.26M$11.76M$14.77M
EBITDA Ratio$0.15$0.28$0.18$0.23
Operating Income$6.20M$7.003M$8.50M$10.60M
Operating Income Ratio$0.09$0.11$0.13$0.17
Other Income/Expenses (Net)-$11.73M$6.48M-$3.44M-$763000.00
Income Before Tax-$5.53M$13.49M$5.06M$9.84M
Income Before Tax Ratio-$0.08$0.20$0.08$0.16
Income Tax Expense-$17000.00$1.30M$65000.00$21000.00
Net Income-$5.51M$12.18M$5.00M$9.82M
Net Income Ratio-$0.08$0.18$0.08$0.15
EPS-$0.29$0.64$0.26$0.52
Diluted EPS-$0.29$0.64$0.26$0.51
Weighted Avg Shares Outstanding$19.25M$19.01M$19.01M$19.01M
Weighted Avg Shares Outstanding (Diluted)$19.32M$19.08M$19.08M$19.08M

Financial performance has remained strong, with revenue growing from $63.41M in Q2 2024 to $67.13M in Q1 2025. Gross profit continued to perform well, with margins at 66% in the latest quarter. Operating income reached $6.20M in Q1 2025, holding a steady 9% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $10.38M. Net income dropped to -$5.51M, keeping EPS at -$0.29. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;